Medical Device Network on MSN
Synchrony Medical bolsters US COPD treatment commercialisation with $5m funding round
Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.
A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?
Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that affects millions of people in the United States and around the world. Despite its prevalence, many individuals ...
Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...
Chronic Obstructive Pulmonary Disease (COPD) is a chronic and irreversible lung condition that is a global public health problem. Globally, approximately 213 million people have COPD, and it was ...
Biomedical startups are taking aim at a deadly lung condition that has long lacked innovative treatments. Chronic obstructive pulmonary disease, caused by smoking and air pollution, hinders breathing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results